Online self-monitoring platform for tracking medication safety and symptoms in people with cancer
Patient Engagement in Using the Technology for Self-Tracking Medication Safety Events
This project will try an online self-monitoring platform to help people with lung, colorectal, breast, or prostate cancer who take cancer medicines at home track medication problems, symptoms, and report concerns to their care team.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Michigan Rogel Cancer Center Academic / other |
| Locations | 1 site (Ann Arbor, Michigan) |
| Trial ID | NCT07291414 on ClinicalTrials.gov |
What this trial studies
This interventional program enrolls adults with lung, colorectal, breast, or prostate cancer who are actively taking and self-managing prescribed cancer medications. Participants use an online platform to record medication-taking experiences, safety concerns, and symptoms at home, supported by educational materials. The protocol includes internet-based monitoring tools, structured interviews, and electronic health record review to compare patient reports with clinical data. Findings will inform whether the digital approach helps patients detect and report medication problems and whether it can be integrated into clinical workflows.
Who should consider this trial
Good fit: Adults (18+) with lung, colorectal, breast, or prostate cancer who are on active cancer treatment, self-manage one or more prescribed cancer medicines, and have access to an internet-capable device or a support person to help are ideal candidates.
Not a fit: People without internet or device access, those who do not speak or read English and lack a helper, and patients whose clinicians advise against participation are unlikely to benefit.
Why it matters
Potential benefit: If successful, it could help patients spot medication problems earlier, reduce harmful interactions or toxicities, and improve communication with clinicians.
How similar studies have performed: Electronic symptom- and toxicity-monitoring programs in oncology have shown benefits for symptom control and patient–clinician communication, though medication-safety-specific platforms are less extensively studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants are adult patients (aged 18 years or older) * Diagnosed with lung, colorectal, breast, or prostate cancer * Are currently receiving active cancer treatments * Are self-managing one or more prescribed cancer medications * Participants must have access to technology devices (smartphone, tablet, computer) to track their experiences or concerns about medication safety events, or their family members can help them access technology devices to track the events or concerns * Speaks and reads English or has a support person (family member or friend) who can assist Exclusion Criteria: * Can't access technology or do not use technology * Do not have access to the internet * Do not speak or read English * Not permitted to participate by their health care providers
Where this trial is running
Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Yun Jiang — University of Michigan Rogel Cancer Center
- Study coordinator: Yun Jiang
- Email: jiangyu@umich.edu
- Phone: 734-763-3705
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.